Yunu Co-Founders Discuss Improving Efficiency and Accuracy in Clinical Trials

Commentary
Video

Jeff Sorenson and Gael Kuhn, Co-founders, Yunu, talk about ways their company has improved efficiency and accuracy in clinical trials for clients such as NCI designated cancer centers.

ACT: Your client list includes NCI-designated cancer centers, large imaging cores, and pharma sponsors. Can you share some examples of how Yunu has improved efficiency and accuracy in their clinical trial imaging workflows?

Kuhn: In order to improve the efficiency of our customers across all of the customer types, we provide a fast study startup with trial configuration able to perform in 30 minutes to an hour and not months, requiring no customization, even for complex scenarios. We also provide fast site activation within the Yunu network with no installation required at all. One additional benefit is we provide we provide one click audit readiness with the ability to defend every measurement on every criteria on any trial performed by any readers.

Sorenson: For sites, we can be set up one of two ways. We can either be set up where we're managing all the sites in a trial, and all of those sites can then of course have the benefit of sharing the same tools, the consistency, the collaboration, and communication. You can set up the readers, the investigators, the study monitors all within that workflow. So that's all of the sites in a trial. That's more of a sponsor or CRO centric use case. We can also be set up to manage all of the trials at a site. So, a very busy NCI designated cancer center can be running hundreds of protocols at the same time. That that means that there are clinical trials operations that really struggle thinking “How do I onboard all of these trials that have potentially low patient enrollment per trial, and still do them all accurately direct them to the correct readers?” So really, you need something that's going to deliver not only the measurements and the data management, but operational efficiency across all of the stakeholders inside of a site when they're doing this work along with their busy clinical routine. We typically see a 30% non-compliance to the protocol inside these busy sites, even the most sophisticated sites, because it's so difficult, and the measurements are so varied. The benefit of Yunu workflows and the connectedness that we create between stakeholders drives this really significant improvement in terms of both efficiency and accuracy. The study staff time related to imaging and delivering these imaging endpoints is reduced by 80% while the radiologists are able to perform twice as many reads in the same amount of time.

Kuhn: Of course, better and faster imaging results impact the overall success of the trial. Imaging is an important endpoint driving the determination of the patient response. Using Yunu, our customers are able to make earlier go/no-go decisions on early phase drug candidates and gain earlier insight by seeing real time imaging results.

Related Videos
Related Content
© 2024 MJH Life Sciences

All rights reserved.